Additional research on the role of IgE in the disorders conventionally perceived as non-IgE-mediated should further clarify their pathogenesis, and future studies on the effects of omalizumab and ligelizumab in autoimmune diseases are likely to shed some light on the mechanism of anti-IgE therapy in these diseases. Here, IGHE is linked to autoimmune disease.